Puma Biotechnology Surging
Puma Biotechnology, Inc.
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2023 Financial Results
Is Puma off the cancer M&A list? With Nerlyx marketing deal, some investors think so | Fierce Pharma
Puma Biotechnology
Puma Biotech gets EU panel nod for breast cancer drug, Health News, ET HealthWorld
Why Puma Biotechnology (PBYI) Stock Is Surging Today - TheStreet
Puma Biotechnology Secures $125 Million Note Purchase by Athyrium Capital | Business Wire
Puma Biotechnology Inc Share Price USD0.0001
Puma Biotechnology Presents Final Results from the Biliary Tract Cohort of the Phase 2 SUMMIT 'Basket' Trial of Neratinib at the ASCO 2022 Annual Meeting | Business Wire
Puma shares nearly triple on drug news, but options smell 'fishy'
Puma Biotechnology, Inc. (PBYI) Stock Price, Quote & News - Stock Analysis
Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib | Seeking Alpha
Puma Biotechnology Stock News (PBYI) - Page 2 - Public.com
Former Puma Biotech Executive Gets U.S. Prison Term for Insider Trading
Puma Biotechnology
Stocks to Watch: Dropbox, Nike, Tronc, Qualcomm, Puma Biotechnology, Invitation Homes, Universal Display - WSJ
Puma Biotechnology falls more than 20%
Puma Biotechnology (PBYI) Stock Climbs On Orphan Drug Designation | Alpha Stock News
PumaBiotech (@pumabiotech) / Twitter
Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote - TheStreet
Puma Biotechnology Executives Under Investigation for Breast Cancer Drug — Schubert Jonckheer & Kolbe
Puma Biotechnology Reports Results of PB272 (neratinib) in P-III NALA Trial for Patients with 2L+ HER2+ Metastatic Breast Cancer #ASCO2019
Puma shares nearly triple on drug news, but options smell 'fishy'
